Pfizer, Bristol-Myers Bloodthinner Halted on Bleeding
This article is for subscribers only.
Pfizer Inc. and Bristol-Myers Squibb Co. halted a trial of their experimental blood thinner after an increase in bleeding outweighed benefits for patients who recently suffered a heart attack or severe chest pain.
The treatment, called apixaban, was being tested to prevent heart complications in patients with a condition known as acute coronary syndrome. Enrollment in the study of 10,800 people in 40 countries was stopped and patients will be taken off the drug, Pfizer and Bristol-Myers said in a statement.